US Patent Issued to VIVALDI BIOSCIENCES on Aug. 18 for "Influenza virus encoding a truncated NS1 protein and a SARS-CoV receptor binding domain" (Austrian, American Inventors)

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,708,663, issued on Aug. 18, was assigned to VIVALDI BIOSCIENCES INC. (Fort Collins, Colo.).

"Influenza virus encoding a truncated NS1 protein and a SARS-CoV receptor binding domain" was invented by Amy Aspelund (Fort Collins, Colo.), Thomas Muster (Vienna) and Markus Wolschek (Vienna).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention refers to a recombinant influenza vims encoding a fusion protein comprising a truncated NS1 protein and a SARS-CoV receptor binding domain, specifically a SARS-CoV-2 RBD, and its use for prophylactic treatment, a pharmaceutical preparation comprising said virus for use in prime boost vaccination and a two-...